ALFA Filings
Every announcement, straight from the exchange
Every Venus Remedies other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
10 announcements
Venus Remedies Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Venus Remedies Limited has announced a change in its Corporate Identification Number (CIN) following the alteration of its Memorandum of Association.
Venus Remedies Limited has informed the exchanges about its social media posts regarding a special window for the re-lodgement of physical share transfer requests.
Venus Remedies informed the exchanges about their social media communications regarding a special window for re-lodgement of physical share transfer requests.
Venus Remedies secured the renewal of its DSIR in-house R&D recognition for its research center. The certification supports ongoing development of novel antimicrobial resistance treatments.
Venus Remedies shared social media links to encourage shareholders to update KYC details. This routine compliance effort ensures regulatory alignment and investor records accuracy.
Venus Remedies Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by P. Chadha and Associates, confirms the company's compliance with SEBI regulations and listing requirements, with no material deviations or observations reported.
Venus Remedies Ltd has issued a social media notice regarding a special window for shareholders to re-lodge transfer requests for physical shares. This follows SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026. The announcement is a regulatory compliance update aimed at assisting shareholders with physical shareholding transitions.
Venus Remedies Limited submitted its compliance certificate under Regulation 74(5) for the quarter ended March 31, 2026. The filing, issued by registrar MUFG Intime India, confirms that security certificates received for dematerialisation were processed and listed within prescribed timelines. This is a routine regulatory disclosure for investors.
Venus Remedies Limited's promoters and promoter group have submitted their annual disclosure under SEBI SAST Regulations for the financial year ended March 31, 2026. The promoters declared that no equity shares were encumbered or pledged during the period, providing transparency regarding the stability of promoter shareholding.